Cue Biopharma (NASDAQ:CUE) — Market Cap & Net Worth
Market Cap & Net Worth: Cue Biopharma (CUE)
Cue Biopharma (NASDAQ:CUE) has a market capitalization of $26.56 Million ($26.56 Million) as of September 18, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #24256 globally and #5225 in its home market, demonstrating a 24.07% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Cue Biopharma's stock price $37.84 by its total outstanding shares 91237736 (91.24 Million). Also see Cue Biopharma assets under control for a full breakdown of the balance sheet.
Cue Biopharma Market Cap History: 2018 to 2026
Cue Biopharma's market capitalization history from 2018 to 2026. Data shows growth from $428.82 Million to $3.45 Billion (14.50% CAGR). Also see Cue Biopharma cash flow conversion for how efficiently the company converts equity into cash flow.
Index Memberships
Cue Biopharma is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.67 Trillion | 0.00% | #692 of 976 |
|
NASDAQ Composite
IXIC
|
$41.95 Trillion | 0.00% | #2278 of 3165 |
Weight: Cue Biopharma's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Cue Biopharma Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Cue Biopharma's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Check today's stock price for Cue Biopharma for real-time trading data and today's change.
Latest Price to Sales (P/S) Ratio
10.71x
Cue Biopharma's market cap is 10.71 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2018 | $428.82 Million | $1.14 Million | -$38.98 Million | 375.30x | N/A |
| 2019 | $1.45 Billion | $3.46 Million | -$36.70 Million | 418.85x | N/A |
| 2020 | $1.14 Billion | $3.15 Million | -$44.78 Million | 361.85x | N/A |
| 2021 | $1.03 Billion | $14.94 Million | -$44.16 Million | 69.06x | N/A |
| 2022 | $260.03 Million | $1.25 Million | -$53.01 Million | 208.86x | N/A |
| 2023 | $240.87 Million | $5.49 Million | -$50.73 Million | 43.87x | N/A |
| 2024 | $99.45 Million | $9.29 Million | -$40.67 Million | 10.71x | N/A |
Competitor Companies of CUE by Market Capitalization
Companies near Cue Biopharma in the global market cap rankings as of September 18, 2026. Review CUE goodwill-adjusted equity ratio to assess the quality of the company's equity after excluding intangible assets.
Key companies related to Cue Biopharma by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #185 globally with a market cap of $130.87 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #337 globally with a market cap of $79.84 Billion USD.
- CSL Ltd (AU:CSL): Ranked #455 globally with a market cap of $60.95 Billion USD ( AU$86.14 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #504 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #185 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.87 Billion | $516.34 |
| #337 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $79.84 Billion | $789.45 |
| #455 | CSL Ltd | AU:CSL | $60.95 Billion | AU$177.56 |
| #504 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $158.07 |
Cue Biopharma Historical Marketcap From 2018 to 2026
Between 2018 and today, Cue Biopharma's market cap moved from $428.82 Million to $ 3.45 Billion, with a yearly change of 14.50%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $3.45 Billion | +12290.31% |
| 2025 | $27.86 Million | -71.98% |
| 2024 | $99.45 Million | -58.71% |
| 2023 | $240.87 Million | -7.37% |
| 2022 | $260.03 Million | -74.80% |
| 2021 | $1.03 Billion | -9.59% |
| 2020 | $1.14 Billion | -21.20% |
| 2019 | $1.45 Billion | +237.77% |
| 2018 | $428.82 Million | -- |
End of Day Market Cap According to Different Sources
On Sep 18th, 2026 the market cap of Cue Biopharma was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $26.56 Million USD |
| MoneyControl | $26.56 Million USD |
| MarketWatch | $26.56 Million USD |
| marketcap.company | $26.56 Million USD |
| Reuters | $26.56 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Cue Biopharma
Cue Biopharma, Inc., a clinical-stage biopharmaceutical company, develops a novel class of injectable therapeutics to selectively engage and modulate targeted, disease relevant T cells in the United States. Its lead drug product candidate is the CUE-401, a novel approach to induce and expand antigen specific Tregs for regulating disease causing autoreactive Teff cells which is in preclinical tria… Read more